Another antibody targeting the soluble IL-13 to prevent receptor binding to both IL-13Rα1 and IL-13Rα2 by, for example, GSK679586 (GlaxoSmithKline, Middlesex, UK) showed no significant improvement in asthma control in patients with severe asthma in a clinical trial [54]. The gene discussed is IL13; the disease is asthma.